NYMC Faculty Publications
Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management
Author Type(s)
Faculty
DOI
10.1007/978-3-031-76882-8_38
Journal Title
Pediatric Surgical Oncology
First Page
587
Last Page
604
Document Type
Article
Publication Date
1-1-2025
Department
Surgery
Keywords
Monoclonal antibodies, Pediatric oncology, Precision medicine, Small molecule inhibitors, Targeted therapy
Abstract
Precision oncology is a treatment strategy designed to tailor molecularly targeted agents to the genomic profile of a tumor. This approach is based on the idea that utilizing therapeutic agents with molecular mechanisms known to target the precise genetic alterations in a tumor will improve outcomes compared to traditional broad-spectrum chemoradiation strategies while decreasing off-target treatment-related toxicities. Precision medicine is well-established in adult oncology and gaining traction in pediatric oncology. Due to the significant differences in genomic alterations between childhood and adult tumors, molecularly targeted therapies exist for only a small subset of pediatric cancers. Clinically utilized molecularly targeted drugs are roughly divided into two categories: small molecule inhibitors and macromolecules, including monoclonal antibodies. Here, we review current targeted treatment strategies utilized in the management of pediatric cancers.
Recommended Citation
Wills, C., & Grant, C. (2025). Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management. Pediatric Surgical Oncology, 587-604. https://doi.org/10.1007/978-3-031-76882-8_38
